NTC and Aspen announce SAHPRA positive outcome for the fixed dose combination of levofloxacin and dexamethasone multidose eye drops

  • Nov 24, 2021

NTC granted the license and commercialisation rights of its patented research and development product to Aspen for South Africa and other African countries, and has provided full technical and regulatory support to Aspen which has secured market authorisation for the product in South Africa.

NTC and STADA announce commercial partnership for portfolio of ophthalmic products in the MENA region

  • Sep 07, 2021

NTC, international pharmaceutical company headquartered in Milan, Italy, and STADA, a global leading pharmaceutical player with significant presence in the Middle East and North Africa (MENA) region, today announce a commercial ophthalmic partnership.

NTC presents the Value report 2021 to its stakeholders

  • July 29, 2021

“Advanced scientific research and technology are the drivers of NTC’s innovation in care practices. While research is the soul of NTC, improving experience of care is our vocation which translates into new and specific therapeutic gestures: simple and intuitive, sustainable, and technically advanced for empowering the patient.” (Letter from the CEO)

Innovation in ophtha made in Italy: NTC has developed the first combination of levofloxacin and dexamethasone eye drops

  • May 13, 2021

NTC, an Italian pharmaceutical company specializing in ophthalmology, has developed the first eyedrops containing a fluoroquinolone wide spectrum antibiotic and a standard of care cortisone for the post-surgical treatment of cataract. The drug reduces the duration of therapy after surgery by 50%.